← Back to headlines
Ocugen Stock Drops Following Mid-Stage Trial Data for GA Therapy
Ocugen's stock has fallen after the release of 12-month data from its mid-stage trial for a geographic atrophy (GA) therapy.
24 Mar, 12:37 — 24 Mar, 12:37
Sources
Showing 1 of 1 sources
Related Stories
Philippines Declares National Emergency Amid Soaring Fuel Prices; Olongapo City Adopts 4-Day Workweek
just now
Northern Samar Lawmaker Seeks Review of High Power Costs in Off-Grid Areas
just now
Farmers group tells Palace: Include us in crisis committee
just now
Philippines Declares National Energy Emergency Amid Middle East Crisis, Fuel Supply Concerns
just now